Last reviewed · How we verify
Valproate, Levocarnitine — Competitive Intelligence Brief
phase 3
Anticonvulsant, Antimanic
Neurology, Psychiatry
Small molecule
Live · refreshed every 30 min
Target snapshot
Valproate, Levocarnitine (Valproate, Levocarnitine) — All India Institute of Medical Sciences. Valproate is a mood stabilizer that works by reducing the activity of certain brain chemicals, while Levocarnitine is involved in energy production within cells.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Valproate, Levocarnitine TARGET | Valproate, Levocarnitine | All India Institute of Medical Sciences | phase 3 | Anticonvulsant, Antimanic |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Anticonvulsant, Antimanic class)
- All India Institute of Medical Sciences · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Valproate, Levocarnitine CI watch — RSS
- Valproate, Levocarnitine CI watch — Atom
- Valproate, Levocarnitine CI watch — JSON
- Valproate, Levocarnitine alone — RSS
- Whole Anticonvulsant, Antimanic class — RSS
Cite this brief
Drug Landscape (2026). Valproate, Levocarnitine — Competitive Intelligence Brief. https://druglandscape.com/ci/valproate-levocarnitine. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab